Abbott Laboratories (ABT) FCF Margin (2009 - 2026)

Abbott Laboratories has disclosed FCF Margin across 18 years of filings, most recently posting 8.2% for Q1 2026.

• FCF Margin for Q1 2026 came in at 8.2%, down 80.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 16.35% (up 63.0% YoY), and the FY2025 annual result was 16.68%, up 154.0% from the prior year.
• FCF Margin came in at 8.2% for Q1 2026 at Abbott Laboratories, down from 22.92% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 22.92% in Q4 2025 to a low of 6.29% in Q1 2024.
• The 5-year median for FCF Margin is 14.66% (2022), against an average of 15.06%.
• Across the five-year window, FCF Margin tumbled 1107 bps in 2023 and surged 722 bps in 2024, its largest moves.
• Abbott Laboratories' FCF Margin stood at 17.01% in 2022, then jumped by 31 bps to 22.29% in 2023, then decreased by 12 bps to 19.57% in 2024, then advanced by 17 bps to 22.92% in 2025, then plunged by 64 bps to 8.2% in 2026.
• The last three FCF Margin figures came in at 8.2% (Q1 2026), 22.92% (Q4 2025), and 20.15% (Q3 2025), per Business Quant data.